Drug news
Repligen files Secreflo with EMA for detection of Pancreatic Duct Abnormalities
Repligen has submitted a marketing authorization application (MAA) for SecreFlo (synthetic human secretin) as an agent to improve the detection of pancreatic duct abnormalities in patients with Pancreatitis. SecreFlo stimulates secretion of watery fluid into the pancreatic ducts. When the ducts are filled with water they are more effectively visualised. FDA decision expected on 21 June 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.